Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.

ABSTRACT: Background:Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. Objective:The purpose of this study was to evaluate in a prospective observational study the utility of an early vedolizumab trough level assay for predicting the first-year vedolizumab therapy outcome. Methods:This prospective observational study included consecutive inflammatory bowel disease patients. We measured vedolizumab trough levels and anti-vedolizumab antibodies at weeks 6 and 14. Clinical outcome was assessed at weeks 6, 14, 22 and 54. The primary endpoint was the correlation between early vedolizumab trough levels and vedolizumab persistence over the fir

SUBMITTER: Guidi L 

PROVIDER: S-EPMC6826518 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature